Suggestions
Sandy Donaldson
CEO & Co-Founder of Impiricus | Accelerating Digital Pharma
Sandy Donaldson is a business professional with a diverse background in entrepreneurship and investing. Here are some key details about Sandy Donaldson:
Professional Experience
Sandy Donaldson currently serves as the CEO and Co-Founder of Impiricus, a company based in the Atlanta Metropolitan Area.23 In addition to this role, Donaldson became an investor in Toucan (JoinToucan.com) in 2022.2
Education
Donaldson has a comprehensive educational background, which includes studying at Harvard Business School.4 Their education began in 1998, suggesting a long-standing commitment to professional development.2
Interests
Sandy Donaldson has expressed interest in language learning, particularly through innovative methods. They have promoted Toucan as a tool for becoming a "polyglot without even knowing it," indicating an appreciation for efficient learning techniques.1
Online Presence
Sandy Donaldson maintains an active online presence:
- LinkedIn: Their profile can be found under the username "sandydonaldson".4
- Twitter: They have a Twitter account with the handle @DonaldsonSandy.1
Location
Based on available information, Sandy Donaldson is located in Atlanta, GA, US.3
Sandy Donaldson's career trajectory demonstrates a blend of entrepreneurial leadership and strategic investing, with a particular focus on innovative technologies and learning solutions.
Highlights
At a time when doctors are busier than ever, 61% of physicians say they waste at least five minutes per visit countering bad information patients get.
One of the top reasons why? Patients often come to an appointment requesting a prescription for a drug they saw on TV that is inappropriate for them.
The problem is less that drug ads are spewing misinformation - those bogus claims usually come from social media and friends in real life - but that the ads can get patients’ hopes up.
A new survey (link in comments) found only 27% of doctors say the medications requested by patients are appropriate for them.
The issue is only increasing: While the top two drugs that patients request after seeing ads are for headache/migraine and immunotherapy for cancer, the No. 3 medication is the GLP-1 weight loss pens soaring in popularity.
The doctors surveyed said the top reason they reject medication requests is because the patient does not meet treatment eligibility. But that doesn’t stop patients from pushing doctors for a prescription - creating a back-and-forth that can be counter-productive.
“You can tell in the first 5-10 minutes whether the patient is going to believe me over the information that they already have printed out in their head,” one immunologist told researchers.
Pharma companies tend to put consumers and doctors into two separate categories and advertise to them in different ways, but I don’t think that has to be the case.
My co-founder, Dr. Osama Hashmi, noted recently how “one of the craziest things about pharma is how little HCPs (and patients) are involved in actually measuring success.”
To help close this gap, we recently decided to sponsor a Fierce Pharma Marketing Award specifically judged by doctors. I was blown away to see 20 submissions for the Impiricus HCP Impact Award, which is about double what the organizers told us to expect. Clearly, the topic struck a nerve.
The finalists will be announced July 25, and the winners unveiled in September. I can’t wait to share some of the best examples!
Can an industry that makes its money off disease afford to focus on preventing people from getting those diseases?
It’s an interesting question I was thinking about for the pharma industry when I saw news that Abbott is ready to an over-the-counter blood sugar monitor in the U.S.
Continuous glucose monitoring devices, long a staple for diabetes patients who get a doctor’s prescription, will now be aimed at the general population for wellness reasons. You stick a bio-sensor on your arm and all your glucose data is sent to your phone in real-time.
Obviously preventative care is sorely needed in this country. Because of the high cost of health care, many people ignore problems until it’s too late - then are stuck with huge hospital bills and a chronic condition. A mere 8% of people undergo routine health screenings.
Studies have found basic measures like eating well and not smoking could cut chronic illness - which make up 3 of every 4 American deaths - by 80%. The phrase “an ounce of prevention is worth a pound of cure” is true everywhere you look: Every dollar spent on childhood immunizations saves $10.30 on direct health care costs, for instance.
Yet the cold reality for pharma companies is that they make most of their money off people not taking care of themselves.
The global wellness industry is pegged at $1.5 trillion a year, which is roughly on par with the pharma industry. But the two industries exist in mostly different worlds.
It’s interesting to see Abbott’s marketing approach for the new Lingo glucose monitors: While they are focusing on consumers, they also want to advertise to doctors under the thinking that patients will ask their physician about it.
It is also a bit of a unique company because it has significant revenue from various sources: pharmaceuticals, medical devices, diagnostics and nutrition. Since 2007, its pharmaceutical revenue is up 18% while sales from everything else is up 52%.
One stat to note: Abbott says its line of glucose monitors is projected to roughly double to $10 billion by 2028 with the over-the-counter edition available.
